Clearmind Medicine Inc (CMND)

Apr 25, 2025, 7:59 AM EDT - 23 hours ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

SPRC

Apr 25, 2025, 7:55 AM EDT - 23 hours ago

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 23, 2025, 8:25 AM EDT - 2 days ago

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

Apr 21, 2025, 9:15 AM EDT - 4 days ago

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

Apr 17, 2025, 7:38 AM EDT - 8 days ago

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

Apr 16, 2025, 8:40 AM EDT - 9 days ago

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Apr 10, 2025, 8:25 AM EDT - 15 days ago

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Apr 8, 2025, 6:55 AM EDT - 18 days ago

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Apr 1, 2025, 8:15 AM EDT - 24 days ago

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

Mar 21, 2025, 9:28 AM EDT - 5 weeks ago

Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

Mar 19, 2025, 7:35 AM EDT - 5 weeks ago

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Mar 18, 2025, 7:32 AM EDT - 5 weeks ago

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

Feb 4, 2025, 8:35 AM EST - 2 months ago

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

Jan 7, 2025, 9:28 AM EST - 3 months ago

Clearmind Medicine Announces Shareholders Meeting Results

Jan 6, 2025, 8:15 AM EST - 3 months ago

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 2, 2025, 7:45 AM EST - 4 months ago

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office

Dec 26, 2024, 6:59 AM EST - 4 months ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Dec 24, 2024, 6:55 AM EST - 4 months ago

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

Dec 16, 2024, 8:37 AM EST - 4 months ago

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

Oct 10, 2024, 8:07 AM EDT - 7 months ago

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

Sep 16, 2024, 4:06 PM EDT - 7 months ago

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sep 12, 2024, 8:20 AM EDT - 8 months ago

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment

Sep 6, 2024, 7:55 AM EDT - 8 months ago

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Aug 29, 2024, 4:25 PM EDT - 8 months ago

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment

Aug 21, 2024, 4:11 PM EDT - 8 months ago

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

Aug 16, 2024, 4:14 PM EDT - 9 months ago

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

Aug 6, 2024, 8:57 AM EDT - 9 months ago

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug

Jul 31, 2024, 7:44 AM EDT - 9 months ago

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research

Jul 19, 2024, 7:55 AM EDT - 10 months ago

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

Jul 16, 2024, 9:02 AM EDT - 10 months ago

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

Jul 16, 2024, 6:03 AM EDT - 10 months ago

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Jul 12, 2024, 8:02 AM EDT - 10 months ago

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

Jun 28, 2024, 7:55 AM EDT - 10 months ago

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

Jun 20, 2024, 7:57 AM EDT - 11 months ago

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

Jun 11, 2024, 7:44 AM EDT - 11 months ago

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

May 10, 2024, 8:24 AM EDT - 1 year ago

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

May 7, 2024, 7:46 AM EDT - 1 year ago

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

Apr 30, 2024, 4:15 PM EDT - 1 year ago

Clearmind Applies to Cease Being a Reporting Issuer in Canada

Apr 17, 2024, 7:49 AM EDT - 1 year ago

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Apr 10, 2024, 7:17 AM EDT - 1 year ago

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Apr 9, 2024, 8:07 AM EDT - 1 year ago

Clearmind Medicine CEO Issues Letter to Shareholders

Mar 27, 2024, 9:12 AM EDT - 1 year ago

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Mar 19, 2024, 7:55 AM EDT - 1 year ago

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

Mar 13, 2024, 2:55 PM EDT - 1 year ago

CSE Bulletin: Delist - Clearmind Medicine Inc. (CMND)

Mar 13, 2024, 8:14 AM EDT - 1 year ago

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Mar 13, 2024, 7:30 AM EDT - 1 year ago

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

Feb 27, 2024, 7:58 AM EST - 1 year ago

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

Feb 23, 2024, 7:06 AM EST - 1 year ago

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Feb 20, 2024, 7:14 AM EST - 1 year ago

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Feb 5, 2024, 7:51 AM EST - 1 year ago

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China